{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:15:29Z","timestamp":1784556929808,"version":"3.55.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Fibromyalgia (FM) is a chronic primary pain condition, associated with widespread musculoskeletal pain, disturbed sleep, fatigue, cognitive dysfunction, and a range of comorbid conditions such as irritable bowel syndrome, and depression. Despite its high prevalence of 2% in the general population, FM continues to pose scientific and clinical challenges in definition, etiology, and day-to-day management. In terms of treatment, FM can be treated with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs).<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> Patients with FM and other chronic primary pain syndromes are known to experience substantial and clinically relevant placebo effects. An update of the placebo responses for various outcomes in the FM population and especially a discussion about clinical implications is therefore needed.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We used data from a large data pool that includes randomized controlled trials (RCTs) examining within-placebo mean change scores of baseline vs. follow-up assessments in FM trials of SSRIs and SNRIs. The primary outcomes were pain, functional disability, and depression and using different scales. We assessed heterogeneity of included trials.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 29 RCTs with <jats:italic>N<\/jats:italic> = 8,453 patients suffering from FM were included in our analysis. Within-placebo mean change scores of baseline vs. follow-up assessments were large for pain (mean change = 2.31, 95% CI: 0.42\u20134.21, <jats:italic>p<\/jats:italic> = 0.017), functional disability (mean change = 3.31, 95% CI: 2.37\u20134.26, <jats:italic>p<\/jats:italic> &amp;lt; 0.000), and depression (mean change = 1.55, 95% CI: 0.92\u20132.18, <jats:italic>p<\/jats:italic> &amp;lt; 0.000). Heterogeneity was found to be large for all outcomes.<\/jats:p><jats:p><jats:bold>Impact:<\/jats:bold> Our results provide preliminary evidence that placebo responses, which also consist of non-specific effects, might play a role in the treatment of FM. Furthermore, we highlight limitations of our analyses and make suggestions for future studies.<\/jats:p>","DOI":"10.3389\/fpain.2021.750523","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T09:16:16Z","timestamp":1638868576000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Placebo Responses and Their Clinical Implications in Fibromyalgia: A Meta-Analysis Using SSRI and SNRI Trials"],"prefix":"10.3389","volume":"2","author":[{"given":"Helen","family":"Koechlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kharko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Pradela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Buechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosima","family":"Locher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.2014.3266","article-title":"Fibromyalgia: a clinical review","volume":"311","author":"Clauw","year":"2014","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0138024","DOI":"10.1371\/journal.pone.0138024","article-title":"The prevalence and characteristics of Fibromyalgia in the 2012 National Health Interview Survey","volume":"10","author":"Walitt","year":"2015","journal-title":"PLoS ONE."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00296-017-3725-2","article-title":"Prevalence of Fibromyalgia in general population and patients, a systematic review and meta-analysis","volume":"37","author":"Heidari","year":"2017","journal-title":"Rheumatol Int"},{"key":"B4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum."},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res."},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2016.08.012","article-title":"Revisions to the 2010\/2011 fibromyalgia diagnostic criteria","author":"Wolfe","year":"2016","journal-title":"Semin Arthritis Rheum."},{"key":"B7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/1472-6963-12-356","article-title":"Survey of physician experiences and perceptions about the diagnosis and treatment of fibromyalgia","volume":"12","author":"Perrot","year":"2012","journal-title":"BMC Health Serv Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/pm\/pnx271","article-title":"A survey of physicians' knowledge and adherence to the diagnostic criteria for fibromyalgia","volume":"19","author":"Kumbhare","year":"2018","journal-title":"Pain Med"},{"key":"B9","first-page":"s46757","article-title":"New guidelines for the diagnosis of fibromyalgia","volume":"57","author":"Heymann","year":"2017","journal-title":"Rev Bras Reumatol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1533-2500.2010.00383.x","article-title":"Identifying fibromyalgia-associated symptoms and conditions from a clinical perspective: a step toward evaluating healthcare resource utilization in fibromyalgia","volume":"10","author":"Silverman","year":"2010","journal-title":"Pain Pract."},{"key":"B11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.berh.2007.03.007","article-title":"Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition","volume":"21","author":"Nielsen","year":"2007","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e12125","DOI":"10.1111\/jabr.12125","article-title":"Central sensitization and the biopsychosocial approach to understanding pain","volume":"23","author":"Adams","year":"2018","journal-title":"J Appl Biobehav Res."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1097\/01.psy.0000146329.63158.40","article-title":"Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables","volume":"66","author":"Thieme","year":"2004","journal-title":"Psychosom Med."},{"key":"B14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ejp.1570","article-title":"Treatment preferences in Fibromyalgia patients: a cross-sectional web-based survey","volume":"24","author":"Valentini","year":"2020","journal-title":"Eur J Pain."},{"key":"B15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/biomedicines5020020","article-title":"Update on treatment guideline in Fibromyalgia syndrome with focus on pharmacology","volume":"5","author":"Kia","year":"2017","journal-title":"Biomedicines."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3389\/fpsyg.2019.01912","article-title":"Goal preferences, affect, activity patterns and health outcomes in women with Fibromyalgia","volume":"10","author":"Pastor-Mira","year":"2019","journal-title":"Front Psychol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2217\/pmt-2016-0006","article-title":"Management of Fibromyalgia syndrome in 2016","volume":"6","author":"Okifuji","year":"2016","journal-title":"Pain Manag"},{"key":"B18","doi-asserted-by":"publisher","first-page":"CD012332","DOI":"10.1002\/14651858.CD012332","article-title":"Oral nonsteroidal anti-inflammatory drugs for Fibromyalgia in adults","volume":"3","author":"Derry","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"B19","unstructured":"198\n            H2332rW\n            BernardyK\n          10.1001\/jama.2008.944191417683012009"},{"key":"B20","doi-asserted-by":"publisher","first-page":"CD011735","DOI":"10.1002\/14651858.CD011735","article-title":"Selective serotonin reuptake inhibitors for Fibromyalgia syndrome","volume":"2015","author":"Walitt","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1111\/j.1526-4637.2006.00178.x","article-title":"Duloxetine and other antidepressants in the treatment of patients with Fibromyalgia","volume":"8","author":"Arnold","year":"2007","journal-title":"Pain Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.mayocp.2016.02.002","article-title":"Opioid use in fibromyalgia: a cautionary tale","volume":"91","author":"Goldenberg","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1027\/2151-2604\/a000181","article-title":"Placebo and nocebo effects in chronic pain patients","volume":"222","author":"Vase","year":"2014","journal-title":"Zeitschrift f\u00fcr Psychol"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2125.2006.02815.x","article-title":"Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials","volume":"63","author":"Gomeni","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.pain.2011.01.050","article-title":"TOC analysis to predict pl: placebo response in drug trials of Fibromyalgia syndrome and painful peripheral diabetic neuropathying clinical score measured in the initial Pain","volume":"152","author":"H\u00e4user","year":"2011"},{"key":"B26","doi-asserted-by":"crossref","first-page":"971sof","DOI":"10.1007\/s40263-019-00662-y","article-title":"Meta-analysis of placebo response in adult antidepressant trials","volume":"33","author":"Li","year":"2019","journal-title":"CNS Drugs."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2017.2432","article-title":"Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis","volume":"74","author":"Locher","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s10067-017-3595-8","article-title":"The placebo effect and its determinants in Fibromyalgia: Meta-analysis of randomised controlled trials","volume":"36","author":"Chen","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1097\/j.pain.0000000000000160","article-title":"A classification of chronic pain for ICD-11","volume":"156","author":"Treede","year":"2015","journal-title":"Pain."},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1002\/ejp.1525","article-title":"Emotional distress: specifying a neglected part of chronic pain","volume":"24","author":"Barke","year":"2020","journal-title":"Eur J Pain."},{"key":"B31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13643-019-1174-6","article-title":"The best treatment option(s) for adult and elderly patients with chronic primary musculoskeletal pain: a protocol for a systematic review and network meta-analysis","volume":"8","author":"Koechlin","year":"2019","journal-title":"Syst Rev"},{"key":"B32","first-page":"726","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions.","author":"Higgins","year":"2020"},{"key":"B33","unstructured":"DigitizeIt\u2014Plot Digitizer Software. Digitize Graphs, Charts and Math Data2021"},{"key":"B34","unstructured":"HigginsJPT\n            GreenS\n          Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]."},{"key":"B35","first-page":"728t33","article-title":"The fibromyalgia impact questionnaire: development and validation","volume":"18","author":"Burckhardt","year":"1991","journal-title":"J Rheumatol."},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pain.2009.03.002","article-title":"Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for childrenelopment and vs of pain intensity","volume":"143","author":"von Baeyer","year":"2009","journal-title":"Pain."},{"key":"B37","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap."},{"key":"B38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","article-title":"The short-form McGill pain questionnaire","volume":"30","author":"Med Melzack","year":"1987","journal-title":"Pain"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry."},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med."},{"key":"B41","doi-asserted-by":"crossref","first-page":"56l","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.134.4.382","article-title":"A. new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry."},{"key":"B43","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain."},{"key":"B45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.biosystems.2017.12.010","article-title":"A test of the adaptive network explanation of functional disorders using a machine learning analysis of symptoms","volume":"165","author":"Melidis","year":"2018","journal-title":"BioSystems"},{"key":"B46","doi-asserted-by":"crossref","first-page":"256ka","DOI":"10.1093\/biomet\/37.3-4.256","article-title":"The comparison of percentages in matched samples","volume":"37","author":"Cochran","year":"1950","journal-title":"Biometrika."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ije\/dyn204","article-title":"Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified","volume":"37","author":"Higgins","year":"2008","journal-title":"Int J Epidemiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B49","first-page":"769","article-title":"Understanding Fibromyalgia and its resultant disability","volume":"13","author":"Grodman","year":"2011","journal-title":"Isr Med Assoc J."},{"key":"B50","article-title":"Work ability in Fibromyalgia: an update in the 21st century","volume":"13","author":"Annie","year":"2017","journal-title":"Curr Rheumatol Rev."},{"key":"B51","article-title":"Work disability and health system utilization in patients with Fibromyalgia syndrome","volume":"13","author":"Al-Allaf","year":"2007","journal-title":"Clin Rheumatol."},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1037\/0033-2909.133.4.581","article-title":"The biopsychosocial approach to chronic pain: Scientific advances and future directions","volume":"133","author":"Gatchel","year":"2007","journal-title":"Psychol Bull."},{"key":"B53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/jpepsy\/jsp066","article-title":"Commentary: a worldwide call for multimodal inpatient treatment for children and adolescents suffering from chronic pain and pain-related disability","volume":"35","author":"Hechler","year":"2010","journal-title":"J Pediatr Psychol"},{"key":"B54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00737-015-0537-9","article-title":"When treating the pain is not enough: a multidisciplinary approach for chronic pelvic pain","volume":"19","author":"Miller-Matero","year":"2016","journal-title":"Archives of Women's Mental Health."},{"key":"B55","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A model of placebo response in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"AJP"},{"key":"B56","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/ejp.1814","article-title":"Identifying goals in patients with chronic pain: a European survey","volume":"25","author":"Goudman","year":"2021","journal-title":"Eur J Pain."},{"key":"B57","doi-asserted-by":"crossref","DOI":"10.1037\/ccp0000159","article-title":"Are reductions in pain intensity and pain-related distress necessary? An analysis of within-treatment change trajectories in relation to improved functioning following interdisciplinary acceptance and commitment therapy for adults with chronic pain","volume":"85","author":"Vowles","year":"2017","journal-title":"J Consult Clin Psychol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3389\/fpsyg.2018.02317","article-title":"When a placebo is not a placebo: problems and solutions to the gold standard in psychotherapy research","author":"Locher","year":"2018","journal-title":"Front Psychol."},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(09)61706-2","article-title":"Biological, clinical, and ethical advances of placebo effects","volume":"375","author":"Finniss","year":"2010","journal-title":"Lancet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/medethics-2015-102986","article-title":"Disclosure of incidental constituents of psychotherapy as a moral obligation for psychiatrists and psychotherapists","volume":"42","author":"Trachsel","year":"2016","journal-title":"J Med Ethics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/PRBM.S75670","article-title":"How can placebo effects best be applied in clinical practice? A narrative review","volume":"8","author":"Bystad","year":"2015","journal-title":"PRBM"},{"key":"B62","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jad.2006.01.020","article-title":"Psychiatrist effects in the psychopharmacological treatment of depression","volume":"92","author":"McKay","year":"2006","journal-title":"J Affect Disord"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.sleep.2015.06.015","article-title":"Durability of treatment response to Zolpidem with three different maintenance regimens: a preliminary study","volume":"16","author":"Perlis","year":"2015","journal-title":"Sleep Med"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1097\/DBP.0b013e3181e121ed","article-title":"Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?","volume":"31","author":"Sandler","year":"2010","journal-title":"J Dev Behav Pediatr."},{"key":"B65","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1097\/j.pain.0000000000000700","article-title":"Open-label placebo treatmentvadjust in chronic low back pain: a randomized controlled trial","volume":"157","author":"Carvalho","year":"2016","journal-title":"Pain."},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.1111\/jebm.12251","article-title":"Effects of placebos without deception compared with no treatment: a systematic review and meta-analysis","author":"Charlesworth","year":"2017","journal-title":"J Evid Based Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1038\/s41598-021-83148-6","article-title":"Effects of open-label placebos in clinical trials: a systematic review and meta-analysis","volume":"11","author":"von Wernsdorff","year":"2021","journal-title":"Sci Rep."},{"key":"B68","doi-asserted-by":"crossref","first-page":"364l","DOI":"10.1017\/S2045796016000809","article-title":"Pre-post effect sizes should be avoided in meta-analyses","volume":"26","author":"Cuijpers","year":"2017","journal-title":"Epidemiol Psychiatr Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.tics.2014.02.010","article-title":"Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention","volume":"18","author":"Ioannidis","year":"2014","journal-title":"Trends Cogn Sci"},{"key":"B70","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/j.pain.0000000000000602","article-title":"Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations","volume":"157","author":"Edwards","year":"2016","journal-title":"Pain."}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2021.750523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T09:16:49Z","timestamp":1638868609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2021.750523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":70,"alternative-id":["10.3389\/fpain.2021.750523"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2021.750523","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]},"article-number":"750523"}}